ML 145

• UNSPSC Description:

  ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM)[1]. ML 145 has no significant activity for GPR35 at either rodent ortholog[2].

• Target Antigen:

  CXCR; GPR35

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Inflammation/Immunology; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/ml-145.html

• Purity:

  97.04

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  CC(/C=C(S1)/C(N(CCCC(NC2=CC(O)=C(C(O)=O)C=C2)=O)C1=S)=O)=C\C3=CC=CC=C3

• Molecular Weight:

  482.57

• References & Citations:

  [1]Heynen-Genel S, et al. Selective GPR35 Antagonists - Probes 1 & 2. National Center for Biotechnology Information (US); 2010-2010 Feb 28.|[2]Laura Jenkins, et al. Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J Pharmacol Exp Ther. 2012 Dec;343(3):683-95.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1164500-72-4